Efficacy and adverse effects of remdesivir in patients with COVID-19 pneumonia: a retrospective study

Bassem Al Hariri; Muad Abdi Hassan; Manish Barman; Vajeeha Haider; Rawan S. Mohamed; Ahmad Alharafsheh; Aram Salehi; Memon Noor Illahi; Mohamed Gaafar Mohamedali

doi:10.18203/2394-6040.ijcmph20251351

Authors

Bassem Al Hariri Department of Medicine, Hamad Medical Corporation, Doha, Qatar; Department of Clinical Medicine, Weill Cornell Medicine, Doha, Qatar https://orcid.org/0000-0002-6858-3375
Muad Abdi Hassan Medical Education Department, Hamad Medical Corporation, Doha, Qatar https://orcid.org/0009-0007-6128-1351
Manish Barman Department of Medicine, Hamad Medical Corporation, Doha, Qatar; Department of Clinical Medicine, Weill Cornell Medicine, Doha, Qatar
Vajeeha Haider Medical Education Department, Hamad Medical Corporation, Doha, Qatar
Rawan S. Mohamed Medical Education Department, Hamad Medical Corporation, Doha, Qatar
Ahmad Alharafsheh Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar
Aram Salehi Department of Medicine, Hamad Medical Corporation, Doha, Qatar; Department of Clinical Medicine, Weill Cornell Medicine, Doha, Qatar
Memon Noor Illahi Department of Medicine, Hamad Medical Corporation, Doha, Qatar
Mohamed Gaafar Mohamedali Department of Medicine, Hamad Medical Corporation, Doha, Qatar

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20251351

Keywords:

COVID-19, Drug-induced liver injury, Elevated liver function tests, Hepatic dysfunction, Remdesivir

Abstract

Background: Remdesivir is an antiviral medication approved by the US FDA to treat COVID-19 in hospitalized patients. However, it has unknown adverse effects and has shown deleterious impacts on several organ systems in randomized controlled trials. This study aims to describe the safety and efficacy of Remdesivir administration in a cohort of 586 patients admitted to a tertiary hospital in Qatar for COVID-19-related reasons.

Methods: A retrospective study of 586 patients admitted with a diagnosis of COVID-19 and treated with Remdesivir were compared to 200 patients with COVID-19 who did not receive Remdesivir.

Results: The rate of mechanical ventilation admission to the intensive care unit was comparable across the two groups (2.35% vs. 2%, p=0.75). Death rates were similar between the two groups (0.02% vs. 0.03%, p=0.43). There was a mean reduction in heart rate within the first three days of antiviral therapy. Negligible variations in serum AST, ALT, ALP, and eGFR levels were detected. Remdesivir-treated patients had a significantly shorter hospital stay.

Conclusions: When using Remdesivir in COVID-19 patients, it's important to be cautious by evaluating baseline parameters and avoiding concurrent use of drugs that could affect the heart, kidneys, or liver.

Metrics

Metrics Loading ...

References

Zampino R, Mele F, Florio LL, Cenatiempo C, Rifino N, Piccolo A, et al. Liver injury in remdesivir-treated COVID-19 patients. Hepatol Int. 2020;14(5):881-3. DOI: https://doi.org/10.1007/s12072-020-10077-3

Antinori S, Cossu MV, Ridolfo AL, Rech R, Bonazzetti C, Pagani G, et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Res. 2020;158:104899. DOI: https://doi.org/10.1016/j.phrs.2020.104899

Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383(19):1827-37. DOI: https://doi.org/10.1056/NEJMoa2015301

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-78. DOI: https://doi.org/10.1016/S0140-6736(20)31022-9

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19-final report. N Engl J Med. 2020;383(19):1813-26. DOI: https://doi.org/10.1056/NEJMoa2007764

Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048-57. DOI: https://doi.org/10.1001/jama.2020.16349

Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology. 2020;72(1):287-304. DOI: https://doi.org/10.1002/hep.31281

Brown AJ, Won JJ, Graham RL, Dinnon KH 3rd, Sims AC, Feng JY, et al. Broad-spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA-dependent RNA polymerase. Antiviral Res. 2019;169:104541. DOI: https://doi.org/10.1016/j.antiviral.2019.104541

U.S. Food and Drug Administration. Available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization# coviddrugs. Accessed on 3 March 2025.

Hendaus MA. Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary. J Biomol Struct Dyn. 2021;39(10):3787-92. DOI: https://doi.org/10.1080/07391102.2020.1767691

WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed antiviral drugs for Covid-19—interim WHO Solidarity trial results. N Engl J Med. 2021;384(6):497-511. DOI: https://doi.org/10.1056/NEJMoa2023184

World Health Organization. Severity of disease classifications and COVID-19 outcomes. Available at: https://www.who.int/standards/classifications/ classification-of-diseases/emergency-use-icd-codes-for-covid-19-disease-outbreak. Accessed 01 January 2025.

Poliseno M, Gallo C, Cibelli DC, Natale A, Politi C, Lalinga AV, et al. Efficacy and safety of remdesivir over two waves of the SARS-CoV-2 pandemic. Antibiotics (Basel). 2021;10(12):1477. DOI: https://doi.org/10.3390/antibiotics10121477

Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. Current pharmacological treatments for COVID-19: what's next? Br J Pharmacol. 2020;177(21):4813-24. DOI: https://doi.org/10.1111/bph.15072

Ferner RE, Aronson JK. Remdesivir in COVID-19. BMJ. 2020;369:m1610. DOI: https://doi.org/10.1136/bmj.m1610

Tchesnokov EP, Feng JY, Porter DP, Götte M. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses. 2019;11(4):326. DOI: https://doi.org/10.3390/v11040326

Simioli F, Nicoletta C, Valentino MR, Buonomo AR, Polverino M, Russo A, et al. Remdesivir in severe COVID-19 and non-invasive ventilation: a real-life experience. Healthcare (Basel). 2021;9(9):1108. DOI: https://doi.org/10.3390/healthcare9091108

van Laar SA, de Boer MGJ, Gombert-Handoko KB, Guchelaar HJ, Zwaveling J, Langebeek R, et al. Liver and kidney function in patients with COVID-19 treated with remdesivir. Br J Clin Pharmacol. 2021;87(11):4450-4. DOI: https://doi.org/10.1111/bcp.14831

Olender SA, Walunas TL, Martinez E, Perez KK, Ringold H, Terry K, et al. Remdesivir versus standard-of-care for severe coronavirus disease 2019 infection: an analysis of 28-day mortality. Open Forum Infect Dis. 2021;8(7):ofab278. DOI: https://doi.org/10.1093/ofid/ofab278

Mozaffari E, Chandak A, Zhang Z, Liang S, Thrun M, Osleeb J, et al. Remdesivir treatment in hospitalized patients with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-cause mortality in a large multicenter observational cohort. Clin Infect Dis. 2022;75(1):e450-8. DOI: https://doi.org/10.1093/cid/ciab875

Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76(2):428-55. DOI: https://doi.org/10.1111/all.14657

Cheema HA, Sohail A, Fatima A, Irfan M, Khurshid A, Mehmood T, et al. Quercetin for the treatment of COVID-19 patients: a systematic review and meta-analysis. Rev Med Virol. 2023;33(2):e2427. DOI: https://doi.org/10.1002/rmv.2427

Meshref M, Hewila IM, Khlidj Y, El-Mahallawy HA, El-Masry TA, Altahan MF, et al. COVID-19-associated cerebrovascular events: a case series study and a literature review of possible mechanisms. Case Rep Neurol. 2023;15(1):11-23. DOI: https://doi.org/10.1159/000529122

Khurshid A, Khurshid M, Sohail A, Cheema HA, Mehmood T, Iqbal M, et al. Facial palsy as a manifestation of COVID-19: a systematic review of cases. Health Sci Rep. 2022;5(6):e887. DOI: https://doi.org/10.1002/hsr2.887